Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 9:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 149 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Aricept (Donepezil hydrochloride) Clear all
Completed Phase 4 Interventional Results available

The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility

NCT00571064
View directory record Official record
Conditions
Mild to Severe Alzheimer's Disease
Interventions
Donepezil HCl
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 1, 2026, 9:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil

NCT02055703
View directory record Official record
Conditions
Healthy Subjects
Interventions
E2609, itraconazole, rifampin, digoxin, donepezil
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 1, 2026, 9:07 AM EDT
Not listed Phase 2 Interventional

The Effect of Donepezil on Wound Healing

NCT04505670
View directory record Official record
Conditions
Wound Heal
Interventions
Donepezil, Placebo oral tablet, Topical Zinc Oxide
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Easton, Maryland
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 1, 2026, 9:07 AM EDT
Completed Phase 2 Interventional

Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior

NCT01495195
View directory record Official record
Conditions
Cocaine Use Disorders
Interventions
High-dose donepezil, Low-dose donepezil, Selegiline, Placebo
Drug
Lead sponsor
Midwest Biomedical Research
Other
Eligibility
21 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 1, 2026, 9:07 AM EDT
Completed Phase 1 Interventional Results available

MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)

NCT04308304
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MK-1942, Donepezil, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Rogers, Arkansas • Hallandale, Florida • Decatur, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 1, 2026, 9:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Treatment of Residual Amblyopia With Donepezil

NCT01584076
View directory record Official record
Conditions
Amblyopia
Interventions
Donepezil, Patching
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Waltham, Massachusetts • Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 1, 2026, 9:07 AM EDT
Completed Phase 3 Interventional

Multicenter Evaluation of Memory Remediation After TBI With Donepezil

NCT02255799
View directory record Official record
Conditions
Traumatic Brain Injury, Memory Deficits
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
4
States / cities
Indianapolis, Indiana • Charlestown, Massachusetts • Elkins Park, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 1, 2026, 9:07 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults

NCT01345864
View directory record Official record
Conditions
Healthy
Interventions
Scopolamine + Donepezil Placebo + PF-04995274 Placebo, Scopolamine + Donepezil 5 mg + PF-04995274 Placebo, Scopolamine + Donepezil 10mg + PF-04995274 Placebo, Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg, Scopolamine + Donepezil Placebo + PF-04995274 15 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 1, 2026, 9:07 AM EDT
Completed Phase 2 Interventional

Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor

NCT00070161
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Radiation Toxicity
Interventions
EGb761, donepezil hydrochloride, cognitive assessment
Dietary Supplement · Drug · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
4
States / cities
Phoenix, Arizona • Rome, Georgia • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Oct 1, 2026, 9:07 AM EDT
Completed Early Phase 1 Interventional Results available

Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain

NCT00452868
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity
Interventions
Donepezil
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
8 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 1, 2026, 9:07 AM EDT
Completed Phase 2 Interventional

Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)

NCT00151398
View directory record Official record
Conditions
Alzheimer Disease
Interventions
lecozotan SR, Donepezil
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
50 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Oct 1, 2026, 9:07 AM EDT
Completed Phase 2 Interventional Results available

BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

NCT02337907
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Placebo, BI 409306, Donepezil
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
55 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Sherman Oaks, California • Orlando, Florida • West Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 1, 2026, 9:07 AM EDT
Terminated Not applicable Interventional Results available

Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease

NCT01082965
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Oct 1, 2026, 9:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions

NCT01260948
View directory record Official record
Conditions
Healthy
Interventions
Donepezil Hydrochloride, Aricept®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
East Grand Forks, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2011 · Synced Oct 1, 2026, 9:07 AM EDT
Not yet recruiting Phase 2 Interventional

An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia Nervosa

NCT06518941
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Donepezil
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 1, 2026, 9:07 AM EDT
Active, not recruiting Early Phase 1 Interventional

Effect of Donepezil on Speech Recognition in Cochlear Implant Users

NCT05438264
View directory record Official record
Conditions
Bilateral Sensorineural Hearing Loss
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 1, 2026, 9:07 AM EDT
Completed Phase 1 Interventional

Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors

NCT00594633
View directory record Official record
Conditions
Brain Tumor, Brain Cancer, Cns Cancer, Cognitive Dysfunction
Interventions
donepezil and questionaires
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 1, 2026, 9:07 AM EDT
Completed Phase 1 Interventional Results available

Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)

NCT04730635
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
55 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Long Beach, California • Hallandale, Florida • Lady Lake, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 1, 2026, 9:07 AM EDT
Completed Phase 3 Interventional Results available

Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors

NCT00369785
View directory record Official record
Conditions
Brain Tumors, Metastatic Disease
Interventions
donepezil hydrochloride, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
16
States / cities
Wichita, Kansas • Lewiston, Maine • Hooksett, New Hampshire + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 1, 2026, 9:07 AM EDT
Completed Phase 4 Interventional Results available

Neural Correlates In Mild Alzheimer's Disease

NCT00477659
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Donepezil hydrochloride
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 1, 2026, 9:07 AM EDT
Completed Phase 4 Interventional

Brain Imaging and Mental Disorders of Aging Intervention

NCT00267163
View directory record Official record
Conditions
Cognition Disorders
Interventions
donepezil, Placebo
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
40 Years to 90 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2008 · Synced Oct 1, 2026, 9:07 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease

NCT02079246
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Idalopirdine 60 mg
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
50 Years and older
Enrollment
1,463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 1, 2026, 9:07 AM EDT
Completed Phase 2 Interventional

VI-1121 for the Treatment Alzheimer's Disease

NCT01428362
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
VI-1121, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
60 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
San Francisco, California • Santa Monica, California • Sunrise, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 1, 2026, 9:07 AM EDT
Terminated Not applicable Interventional Results available

Comparative Research of Alzheimer's Disease Drugs

NCT01362686
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
Donepezil, Galantamine, Rivastigmine
Drug
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Fishers, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 1, 2026, 9:07 AM EDT